THE ARTEMISININ ENTERPRISE - GHDonline

ACTs. To address these and other challenges, the market has responded (or could respond)
through four different types of strategies:
• better demand forecasting through the gathering and analysis of more and better data;
more collaboration between stakeholders and developing an agreed methodology;
• multi‐pronged fiscal responses including access to larger amount of funds, more
predictable flow of funds, longer period of funding and more flexible use of funds (eg
for creating a buffer stock of artemisinin or ACTs);
• policy response to address issues related to resistance (for example, prohibiting the
registration and use of artemisinin monotherapy); increasing availability of drugs
through fast track registration of new ACTs; establishing ACTs as a drug of choice and
making ACTs an ʺover the counterʺ drug, etc;
• technology response to stabilize the supply of artemisinin (by increasing yield and
exploring the possibility of creating a non‐agricultural‐based artemisinin product);
discover and develop the next generation antimalarials in case of resistance to ACTs,
etc.
While other stakeholders are focusing on the demand, fiscal and policy‐based responses, the
AE partners are focused on the ʺtechnology responseʺ. The rest of this document reports on
the proceedings of the AE Conference, including the outputs of the breakout group
discussions, the AE technologiesʹ timelines, impact on the market and recommendations.
30